IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have earned an average rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $53.67.

Several research analysts have weighed in on IDYA shares. Cantor Fitzgerald started coverage on IDEAYA Biosciences in a research report on Tuesday, October 15th. They issued an “overweight” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research report on Monday, November 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Citigroup dropped their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Finally, Stephens started coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price on the stock.

Institutional Investors Weigh In On IDEAYA Biosciences

Several hedge funds have recently modified their holdings of the business. Allworth Financial LP boosted its holdings in IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 800 shares during the period. Covestor Ltd lifted its stake in shares of IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares during the period. Quest Partners LLC bought a new position in IDEAYA Biosciences during the second quarter valued at about $41,000. Comerica Bank raised its holdings in IDEAYA Biosciences by 723.5% in the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after acquiring an additional 1,324 shares in the last quarter. Finally, US Bancorp DE lifted its position in shares of IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after acquiring an additional 689 shares during the period. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Trading Up 0.8 %

NASDAQ:IDYA opened at $26.99 on Thursday. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.58 and a beta of 0.86. IDEAYA Biosciences has a 1-year low of $25.20 and a 1-year high of $47.74. The business’s fifty day moving average price is $29.84 and its 200 day moving average price is $35.48.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period last year, the business earned ($0.46) EPS. Equities analysts forecast that IDEAYA Biosciences will post -2.46 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.